- Home
- NAAS vs IXHL Comparison
NAAS vs IXHL Comparison
Compare NAAS & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAAS | IXHL |
|---|---|---|
| Founded | 2019 | 2001 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7M | 37.0M |
| IPO Year | 2017 | 2024 |
Fundamental Metrics
Financial Performance| Metric | NAAS | IXHL |
|---|---|---|
| Price | $3.27 | $3.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.9K | ★ 241.9K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.64 | $0.16 |
| 52 Week High | $4.54 | $6.39 |
Technical Indicators
Market Signals| Indicator | NAAS | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 50.46 | 41.34 |
| Support Level | $2.85 | $3.07 |
| Resistance Level | $3.25 | $4.12 |
| Average True Range (ATR) | 0.26 | 0.25 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 39.47 | 9.73 |
Price Performance
Historical ComparisonAbout NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.